There are many treatment options that may help with OA knee pain2-5

How can I treat my OA Knee Pain?

OA of the knee is a fairly common condition. While there is no cure for it, the good news is that there are various treatment options that can help relieve your pain and maximize the way your knee functions.6

About 37% of adults over 60 are affected by oa of the knee7

The Pros and Cons of Treatment for OA of the Knee2-5

Treatments

Over-the-counter or prescription pain relievers

Pros

Help relieve pain

Cons

Relief only lasts a short amount of time

Corticosteroids

Pros

Help relieve pain

Cons

May have side effects like pain, stiffness, and swelling of the joint

Can lead to further cartilage breakdown

Hyaluronic acid (HA) injections

Pros

Help reduce pain and inflammation and improve function

Minimal complications

Cons

Some HA injections may cause more swelling of the joint

Want to know more about OA of the knee? Watch as Dr Ferkel talks about common symptoms and the overall goal of treatment.

What makes HA Injections Different from Other Treatments?

HA is found naturally throughout the body, especially in the knee joint. Healthy HA has high molecular weight and a linear structure. It works with the natural knee fluid to cushion and lubricate the knee so it can withstand the demands of daily life. Unfortunately, HA in the knee can decrease and breakdown over time which may lead to increased pain, swelling, and injury. That’s where HA injections can help.2,8,9

HA injections are administered by your doctor and are injected directly into your knee, but not all HA’s are the same. HA injections with high molecular weight and a linear structure may provide additional benefits.9,10

Repeat Injections of High Molecular Weight HA
May help enhance the way the synovial fluids’ HA move throughout your knee—improving your knee joint’s ability to make its own HA11-13

High Molecular Weight LINEAR HA’s MAY Provide2,9,10:

Physical Benefits

Provides lubrication

Increases shock absorption

Cellular Benefits

Reduces pain and inflammation

Helps protect cartilage and decreases future wear and tear

Helps your body create more of your own naturally made HA

clinical studies have shown that using HA injections in the early Stages of OA of the knee can help decrease future wear and tear 2,9,10

Understanding and Treating OA of the Knee

Gaining a better understanding of OA of the knee is the first step towards finding a treatment that works for you. This owner’s manual will help educate you on what causes OA of the knee and how different treatment options can help.

Download
(English)

Download
(Spanish)

about EUFLEXXA

Find out how EUFLEXXA stands apart

See the Difference

Proven Results

Discover the clinical study results EUFLEXXA had in patients with OA knee pain.

Explore the Results
  1. Rolling 12 month average of IQVIA claims data based on unique patients (November 2021).
  2. Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskeletal Disorders. 2015;16:321.
  3. Arroll B, Goodyear-Smith F. Corticosteroid injections for osteoarthritis of the knee: meta-analysis. BMJ. 2004;10(328):1-5.
  4. Kompell A, Roemer F, Murakami A, et al. Intra-articular corticosteroid injections in the hip and knee: perhaps not as safe as we thought? Radiology. 2019;293:656-663.
  5. Migliore A, Procopio S. Effectiveness and utility of hyaluronic acid in osteoarthritis. Clin Cases Miner Bone Metab. 2015;12(1):31-33.
  6. Altman RD, Rosen JE, Bloch DA, et al. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX Trial). Semin Arthritis Rheum. 2009;39(1):1-9.
  7. Grace L, McAlindon T, Hawker G, et al. Symptom assessment in knee osteoarthritis needs to account for physical activity level. Arthritis Rheumatol. 2015;67(11):2897-2904.
  8. Sirin D, Kaplan N, Yilmaz I, et al. The association between different molecular weights of hyaluronic acid and CHAD, HIF-1α, COL2A1 expression in chondrocyte cultures. Exp Ther Med. 2018;15:4205-4212.
  9. Nicholls M, et al. A comparison between rheological properties of intra-articular hyaluronic acid preparations and reported human synovial fluid. Adv Ther. 2018;35:523-530.
  10. Yang C, Cao M, Liu H, et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem. 2012;287(51):43094-43107.
  11. Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int. 1987:7(3):113-122.
  12. Concoff A, Sancheti P, Niazi F, Shaw P, Rosen J. The efficacy of multiple versus single hyaluronic acid injections: a systemic review and meta-analysis. BMC Musculoskelet Disord. 2017 Dec 21;18(1):542. doi:10.1186/s12891-017-1897-2
  13. Loknauth J, Driscoll KE, Bendele A, Niazi F, Liang A, Larsen CC. Viscosupplementation may preserve tibial cartilage and collagen in osteoarthritis: findings from a preclinical model of osteoarthritis. J Exp Orthop. 2020 May 31;7(1):39. doi: 10.1186/s40634-020-00256-4

Please see Important Safety Information and Full Prescribing Information

Indication

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified healthcare professional.

Important Safety Information

  • Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.
  • You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.
  • EUFLEXXA has not been tested in pregnant women, women who are nursing or in children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time.)
  • The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

Please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.

Indication

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified healthcare professional.

Important Safety Information

  • Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.
  • You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.
  • EUFLEXXA has not been tested in pregnant women, women who are nursing or in children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time.)
  • The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

Please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.

 

The content on this website is for informational purposes only and is not intended to replace a discussion with a healthcare professional.

Get a head start: Check your coverage and sign up for your EUFLEXXA coverage certificate

Check your coverage below to see if you may be covered through your insurance provider for EUFLEXXA

EUFLEXXA is covered on Medicare Part B*, and is covered by most private plans. Your healthcare provider’s office will check your benefits.

Your EUFLEXXA coverage certificate will let you know if you are covered. Bring your certificate to your doctor to discuss EUFLEXXA as a possible treatment option for you.

MM slash DD slash YYYY
Address(Required)

By signing up, I am giving Ferring Pharmaceuticals Inc. (“Ferring”) permission to store and use the information that I have provided. I understand and agree that my information will be used by Ferring (or companies working on Ferring’s behalf) to contact me by telephone, email, or mail to provide me with information about products or services that may be of interest to me. I understand that my information will be treated as described in Ferring’s Privacy Notice, which provides details about my privacy rights. Also, I understand that I may opt out of the database at any time by making the request at Data Subject Form, or by calling 1-888-FERRING, Monday through Friday, 8 AM to 7 PM ET to speak to a representative or leave a voicemail. This statement may be updated from time to time.

This program assists in the determination of whether treatment could be covered by the applicable third-party payer based on coverage guidelines provided by the payer and patient information provided by you. Third-party reimbursement is affected by many factors. Therefore, we make no representation or guarantee that full or partial insurance reimbursement or any other payment will be available. This is not intended to be medical advice. Please consult with your healthcare provider to determine which treatment may be right for you.

*Out-of-pocket cost may apply. Please check with your doctor.

This website may contain links to, or be accessed from links on, other worldwide websites. Ferring does not have responsibility for or control the contents, availability, operation or performance of other websites to which this website may be linked or from which this website may be accessed.

Ferring makes no representation regarding the content of any other websites which you may access from this website.

Ok Cancel